Medtech research spending set to slow in 2022
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
Up-and-down test sales and a bigger Medtronic: medtech in 2028
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
The next generation of diabetes technology
New devices are coming, but the real advances will involve combinations.
Abbott finally enters the leadless pacemaker fray
Remember Nanostim? It’s back – in a modified form, sold by a different company, and under another name.
